Marsden Matthew D, Zack Jerome A
David Geffen School of Medicine at UCLA, 615 Charles E Young Drive South, BSRB 188-10, Los Angeles, CA 90095, USA, Tel.: +1 310 206 2152.
Future Virol. 2010 Jan 1;5(1):97-109. doi: 10.2217/fvl.09.70.
HAART has succeeded in reducing morbidity and mortality rates in patients infected with HIV. However, a small amount of replication-competent HIV can persist during HAART, allowing the virus to re-emerge if therapy is ceased. One significant source of this persistent virus is a pool of long-lived, latently infected CD4(+) T cells. This article outlines what is known about how this reservoir is established and maintained, and describes the model systems that have provided insights into the molecular mechanisms governing HIV latency. The therapeutic approaches for eliminating latent cells that have been attempted are also discussed, including how improvements in understanding of these persistent HIV reservoirs are being used to develop enhanced methods for their depletion.
高效抗逆转录病毒疗法(HAART)已成功降低了HIV感染患者的发病率和死亡率。然而,在HAART治疗期间,仍有少量具有复制能力的HIV能够持续存在,一旦停止治疗,病毒就可能再次出现。这种持续存在的病毒的一个重要来源是一群长寿的、潜伏感染的CD4(+) T细胞。本文概述了关于这个病毒库如何建立和维持的已知信息,并描述了为深入了解控制HIV潜伏的分子机制提供了见解的模型系统。还讨论了尝试消除潜伏细胞的治疗方法,包括如何利用对这些持续存在的HIV病毒库的进一步了解来开发更有效的清除方法。